Hellenic Institute for the Study of Sepsis

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 0

No TA breakdown available.

R&D Momentum

43/100

Pipeline Velocity

11/100

Trial Completion Rate

93/100

Pipeline Concentration

100/100

Pipeline Freshness

72/100

Activity

Recent Activity

Last 14 days

Nov 4, 2026

Recruiting

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

Nov 4, 2026

Withdrawn

Gut-derived Incretin Hormones in the Pathophysiology of Type 1 Diabetes Mellitus; Effect of Metformin Treatment

Nov 4, 2026

Recruiting

THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

Earlier

Sep 22, 2026TrialViscoelastic Coagulation Monitor as an Early Index of Sepsis in Patients Admitted With Infection at the Emergency Department: The VISION Project

Jul 7, 2026TrialA Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Sars-Cov-2

Mar 22, 2025TrialEmapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Feb 12, 2024TrialClarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Sep 6, 2023TrialSafety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

4 more events

Mar 6, 2023TrialUse of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

Apr 13, 2022TrialBezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Apr 1, 2022TrialSTS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

Jul 29, 2021TrialPersonalized Immunotherapy in Sepsis

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Unknown / Other

Safety and Efficacy

Anakinra or rhIFNγ

Unknown / Other

Safety and Efficacy

Anakinra or rhIFNγPhase 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)